June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Risk of Non-infectious Uveitis with Female Hormonal Therapy in a Large Healthcare Claims Database
Author Affiliations & Notes
  • Tian Xia
    Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Lucia Sobrin
    Department of Ophthalmology, Mass Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, United States
  • Yinxi Yu
    Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • gayatri susarla
    Department of Ophthalmology, Mass Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, United States
  • Weilin Chan
    Department of Ophthalmology, Mass Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, United States
  • John H Kempen
    Department of Ophthalmology, Mass Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, United States
    Discovery Eye Center, MyungSung Christian Medical Center, Addis Ababa, Ethiopia
  • Rebecca Hubbard
    Department of Biostatistics, Epidemiology & Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Brian L VanderBeek
    Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Tian Xia, None; Lucia Sobrin, None; Yinxi Yu, None; gayatri susarla, None; Weilin Chan, None; John Kempen, Sight for Souls (F); Rebecca Hubbard, Humana (F), Pfizer (F); Brian VanderBeek, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 2053. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tian Xia, Lucia Sobrin, Yinxi Yu, gayatri susarla, Weilin Chan, John H Kempen, Rebecca Hubbard, Brian L VanderBeek; Risk of Non-infectious Uveitis with Female Hormonal Therapy in a Large Healthcare Claims Database. Invest. Ophthalmol. Vis. Sci. 2020;61(7):2053.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine if female hormonal therapy (FHT) increases the incidence of noninfectious uveitis

Methods : A retrospective cohort study was conducted comparing women enrolled in a national insurance plan exposed to FHT and matched unexposed controls. All women prescribed an FHT were eligible. Exclusion occurred in exposed and unexposed for use of an estrogen-modifying drug or disease, prior uveitis diagnosis, having <2 years of time in plan or no prior ophthalmic exam. To account for possible differences between the exposed and unexposed cohorts, a propensity score for FHT exposure was created and inverse probability of treatment weighting (IPTW) was used. Weighted Cox proportional hazards regression modeling estimated hazard ratios (HR) for noninfectious uveitis relative to FHT exposure.
The primary outcome was incident non-infectious uveitis defined as a new diagnosis code for non-infectious uveitis followed by a second instance of a non-infectious uveitis code within 120 days. A similar, but alternative outcome was also defined based on corticosteroid prescription within 120 days of the initial uveitis diagnosis instead of a second uveitis diagnosis code. Sub-analyses were conducted for anatomic subtypes of uveitis and those aged above and below 44 years.

Results : 217,653 FHT-exposed patients were matched to 928,408 controls. After IPTW, Cox regression analysis showed no difference in hazard for uveitis in exposed relative to unexposed [HR=0.99;95% Confidence Interval (CI):0.83-1.17,P=0.87] . For the alternative uveitis definition, FHT exposed individuals had a higher hazard compared to unexposed [HR=1.21;95%CI:1.04-1.41,P=0.01]. Sub-analyses showed FHT exposed had a higher hazard for anterior uveitis (HR=1.23;95%CI:1.05-1.45,P=0.01) for the alternative outcome definition but not for the primary(HR=1.05;95%CI:0.87-1.26,P=0.62). After age stratification, FHT cohort over 45 years of age had an increased hazard for the alternative outcome definition (HR=1.23;95%CI:1.03-1.46,P=0.03). A similar HR(HR=1.22) was seen for women ≤44 years of age, but it did not reach significance(P=0.20).

Conclusions : Exposure to FHT confers a higher hazard for uveitis when defined as a diagnosis with corticosteroid treatment. Although FHT is safe in the vast majority of uveitis patients, the possibility of a small increased risk with FHT should be considered when managing patients with uveitis.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×